Back to Results
Non-Inteventional Fresh Tumor Tissue
Title |
Analysis Of Cell Count, Viability, And Of Fresh Newly Diagnosed Glioblastoma Tissue |
Therapeutic Area |
Glioblastoma
|
Principal Investigator |
Julian Wu, MD |
Min Age |
18 Years |
Gender |
All |
Contact |
Sarah Sexton 617-636-5558
NCCCR@tuftsmedicalcenter.org
|
tilize fresh tumor tissue to aid the development of future therapies for brain cancer.
Briefly, a cell immunotherapy consisting of a patient’s autologous glioblastoma tumor cells, called ‘IGV-001’, is being tested in clinical trials. In order to advance clinical and product development of IGV-001, Imvax is seeking access to patient material to test key product parameters in a laboratory setting.
The device used to collect the tissue, the Myriad multifunctional device enabling suction, resection, and collection of tumor tissue (see NICO Myriad Use Manual) is an FDA-approved device that is safe
Inclusion Criteria
- English speaking
- Any individual >18 years old
- Patients eligible for and undergoing craniotomy for diagnostic and therapeutic purposes. Please note: Patients undergoing craniotomy for presumed diagnosis of Grade IV GBM are eligible.
Exclusion Criteria
N/A
Study Requirements
The patient signs the informed consent form. Once the surgery is performed and the samples collected, the study period is concluded.